Janssen applies to FDA for New Indication of XARELTO® for Peripheral Artery Disease
The Janssen Pharmaceutical Companies of Johnson & Johnson revealed on Monday the submission of the supplemental New Drug Application (sNDA)
Read more
Cardiovascular
BMS boosts cardiovascular pipeline with $13.1 Billion MyoKardia buy
Bristol Myers Squibb is strengthening its cardiovascular pipeline through a $13.1 Billion acquisition of biotech firm MyoKardia. The $13.1 Billion
Read more